Biology:B-cell maturation antigen

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens

A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example
BCMA TALL-1 binding domain
PDB 1oqd EBI.jpg
crystal structure of stall-1 and bcma

B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.

TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF).[1][2][3]

Serum B-cell maturation antigen (sBCMA) is the cleaved form of BCMA, found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM).[4]


The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.[3]


TNFRSF17 has been shown to interact with the B-cell activating factor TNFSF13B.[5][6] A conserved domain at the N-terminus, BCMA TALL-1 binding domain, is required for binding to the TNFSF13B.[5]

Clinical significance

TNFRSF17 is implicated in leukemia, lymphomas, and multiple myeloma[7] (see the "Mitelman Database" [8] and the Atlas of Genetics and Cytogenetics in Oncology and Haematology,[9]).

As a drug target

An antibody-drug conjugate Belantamab mafodotin (GSK2857916) has evaluated in patients with relapsed/refractory multiple myeloma.[10] Belantamab mafodotin was approved in the United States in August 2020 for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.[11]

A Phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against BCMA in myeloma patients refractory to a proteasome inhibitor or immunomodulatory drug, and who had received an anti-CD38 antibody has been completed.[12]

ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA).[13] (As of June 2021), it is undergoing clinical trials for the treatment of multiple myeloma.[14] On 21 April 2021, the FDA granted Regenerative Medicine Advanced Therapy status to ALLO-715.[15] ALLO-715 is being investigated at Memorial Sloan Kettering Cancer Center and the Mayo Clinic[16] as part of the UNIVERSAL trial for multiple myeloma, on its own and in conjunction with the selective gamma secretase inhibitor nirogacestat.[14][17]


  1. "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma". The EMBO Journal 11 (11): 3897–904. November 1992. doi:10.1002/j.1460-2075.1992.tb05482.x. PMID 1396583. 
  2. "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed". Nucleic Acids Research 22 (7): 1147–54. April 1994. doi:10.1093/nar/22.7.1147. PMID 8165126. 
  3. 3.0 3.1 "Entrez Gene: TNFRSF17 tumor necrosis factor receptor superfamily, member 17". 
  4. "Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies". The Journal of Allergy and Clinical Immunology: In Practice 8 (1): 283–291.e1. January 2020. doi:10.1016/j.jaip.2019.08.012. PMID 31430592. 
  5. 5.0 5.1 "Ligand-receptor binding revealed by the TNF family member TALL-1". Nature 423 (6935): 49–56. May 2003. doi:10.1038/nature01543. PMID 12721620. Bibcode2003Natur.423...49L. 
  6. "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1". Proceedings of the National Academy of Sciences of the United States of America 97 (16): 9156–61. August 2000. doi:10.1073/pnas.160213497. PMID 10908663. Bibcode2000PNAS...97.9156S. 
  7. "TNFRSF17 (tumor necrosis factor receptor superfamily, member 17)". 
  8. "Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer". 
  9. "Atlas of Genetics and Cytogenetics in Oncology and Haematology". 
  10. "Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study". The Lancet. Oncology 21 (2): 207–221. February 2020. doi:10.1016/s1470-2045(19)30788-0. PMID 31859245. 
  11. "FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma". Clinical Cancer Research 28 (21): 4629–4633. November 2022. doi:10.1158/1078-0432.CCR-22-0618. PMID 35736811. 
  12. "Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)" (in en). Blood 134 (Supplement_1): 577. 2019-11-13. doi:10.1182/blood-2019-121731. ISSN 0006-4971. 
  13. "ALLO-715, an Allogeneic BCMA CAR T Therapy Possessing an Off-Switch for the Treatment of Multiple Myeloma". Blood 132 (Supplement 1): 591. 2018-11-29. doi:10.1182/blood-2018-99-119227. ISSN 0006-4971. 
  14. 14.0 14.1 Clinical trial number NCT04093596 for "Allogene Therapeutics" at
  15. "FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma" (in en). 
  16. "Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)" (in en). 
  17. "ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field" (in en). 2020-12-07. 

External links

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article incorporates text from the public domain Pfam and InterPro: IPR015337